ATE281170T1 - Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen - Google Patents

Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen

Info

Publication number
ATE281170T1
ATE281170T1 AT97917945T AT97917945T ATE281170T1 AT E281170 T1 ATE281170 T1 AT E281170T1 AT 97917945 T AT97917945 T AT 97917945T AT 97917945 T AT97917945 T AT 97917945T AT E281170 T1 ATE281170 T1 AT E281170T1
Authority
AT
Austria
Prior art keywords
steroids
respiratory diseases
treat asthma
asthma
treat
Prior art date
Application number
AT97917945T
Other languages
English (en)
Inventor
Alastair G B O'brien I Stewart
Original Assignee
Amrad Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN9766A external-priority patent/AUPN976696A0/en
Priority claimed from AUPN9918A external-priority patent/AUPN991896A0/en
Application filed by Amrad Operations Pty Ltd filed Critical Amrad Operations Pty Ltd
Application granted granted Critical
Publication of ATE281170T1 publication Critical patent/ATE281170T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97917945T 1996-05-09 1997-05-09 Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen ATE281170T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN9766A AUPN976696A0 (en) 1996-05-09 1996-05-09 Treatment of asthma and airway diseases
AUPN9918A AUPN991896A0 (en) 1996-05-20 1996-05-20 Treatment of asthma and airway diseases
PCT/AU1997/000286 WO1997042958A1 (en) 1996-05-09 1997-05-09 Treatment of asthma and airway diseases

Publications (1)

Publication Number Publication Date
ATE281170T1 true ATE281170T1 (de) 2004-11-15

Family

ID=25645169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917945T ATE281170T1 (de) 1996-05-09 1997-05-09 Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen

Country Status (8)

Country Link
US (2) US5962445A (de)
EP (1) EP0923376B1 (de)
JP (1) JP4228116B2 (de)
CN (1) CN1245982C (de)
AT (1) ATE281170T1 (de)
CA (1) CA2253943C (de)
DE (1) DE69731473T2 (de)
WO (1) WO1997042958A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
EP1124545B1 (de) 1998-08-11 2004-12-15 EntreMed, Inc. Verwendung von 2-methoxyestradiol als fungizide
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
WO2003063787A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
RU2236219C2 (ru) * 2002-06-03 2004-09-20 Чепурная Мария Михайловна Способ лечения бронхиальной астмы у детей в приступном периоде
WO2004045556A2 (en) * 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
KR20050104383A (ko) * 2003-02-20 2005-11-02 유니버시티 오브 피츠버그 폐 고혈압의 치료를 위한 에스트라디올 대사물
US20070275935A1 (en) * 2003-05-13 2007-11-29 Stewart Alastair G Estratriene Derivatives
EP1633367A2 (de) 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogene mittel
US8592368B2 (en) * 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
CA2558014A1 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2580264A1 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
US20070048230A1 (en) * 2005-08-24 2007-03-01 Walter Parsadayan Pheromone compositions and methods
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
CA2646065C (en) 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
EP2117529A4 (de) * 2007-02-06 2010-07-28 Res Foundation Of The State Un Verfahren zur behandlung von erkrankungen im zusammenhang mit veränderter ige-regulierung
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102793689A (zh) * 2012-09-12 2012-11-28 郑州大学 一种抗肿瘤药物2-甲氧基雌二醇干粉吸入剂及其制备方法
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
PL244930B1 (pl) * 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274056A (en) * 1963-05-17 1966-09-20 American Cyanamid Co Methods for lowering blood cholesterol and compositions of alkali metal 2-methoxyestra-1, 3, 5(10)-trien-3-ol-17-one sulfate
US4427669A (en) * 1982-06-28 1984-01-24 The Board Of Regents Of The University Of Nebraska Contraceptive
US4420428A (en) * 1982-12-27 1983-12-13 E. R. Squibb & Sons, Inc. 16-Ketoandrostene-17-dithioketals
DE3344834A1 (de) * 1983-12-08 1985-06-13 Schering AG, 1000 Berlin und 4709 Bergkamen Neue hydrocortison-und prednisolon-derivate
US4529548A (en) * 1984-05-07 1985-07-16 E. R. Squibb & Sons, Inc. 17β-(substituted thio)androstenes
US4529547A (en) * 1984-06-20 1985-07-16 E.R. Squibb & Sons, Inc. 17-(substituted thio)-17-(substituted dithio)androstenes
DK336485A (da) * 1984-07-25 1986-01-26 Hovione Int Ltd Fremgangsmaade til fremstilling af et diisopropylaetersolvat af beclomethason-17,21-dipropionat
RU2028083C1 (ru) * 1987-07-10 1995-02-09 Андрюкин Алексей Алексеевич Способ лечения стероидозависимой бронхиальной астмы
US5116829A (en) * 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
CA2111002C (en) * 1991-06-10 2000-08-22 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
ATE339952T1 (de) * 1991-06-10 2006-10-15 Schering Corp Fluorchlorkohlenwasserstofffreie aerosolformulierungen
CA2078804C (en) * 1991-10-01 2003-02-25 Takehiko Suzuki Manufacture and use of novel glycosides of catechol estrogens
DE69311742T2 (de) * 1992-12-24 1998-01-08 Rhone Poulenc Rorer Ltd Neue steroide
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JPH08165242A (ja) * 1994-12-09 1996-06-25 Kunio Yagi 抗動脈硬化剤

Also Published As

Publication number Publication date
CA2253943A1 (en) 1997-11-20
US5962445A (en) 1999-10-05
CN1218401A (zh) 1999-06-02
CA2253943C (en) 2009-09-29
JP4228116B2 (ja) 2009-02-25
CN1245982C (zh) 2006-03-22
JP2000507923A (ja) 2000-06-27
DE69731473D1 (de) 2004-12-09
WO1997042958A1 (en) 1997-11-20
US6200966B1 (en) 2001-03-13
EP0923376A4 (de) 2001-09-26
DE69731473T2 (de) 2005-10-27
EP0923376B1 (de) 2004-11-03
EP0923376A1 (de) 1999-06-23

Similar Documents

Publication Publication Date Title
ATE281170T1 (de) Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ATE518520T1 (de) Verwendung von mometason-furoat zur behandlung von luftweg- und lungenerkrankungen
ATE259215T1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
FI972793A0 (fi) Nebivololin käyttö antiaterogeenisenä aineena
DE69719798D1 (de) Periphäre verabreichung von glp-1 analogen und derivate zur reguleirung der fettleibigkeit
YU7797A (sh) Kombinovana terapija za osteoporozu
DE69521521D1 (de) Mono- oder polyfunktionelle konjugate von polylysine
ATE207351T1 (de) Verwendung vonmodafinil zur behandlung von atemstillstand im schlaf und zentral erregten atembeschwerden
BR9610277A (pt) Derivados de piperazino como antagonistas de neurowuinina
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
DE60002885D1 (de) Wässrige formulierung zur nasalen verabreichung
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69635305D1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
NO20064964L (no) Behandling av svekket respiratorisk funksjon
DE69535267D1 (de) Verwendung zur verabreichung von östrogen
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE60323973D1 (de) Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
SE9901273D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties